Dingell, Stupak ask firms to remove BPA
This article was originally published in The Tan Sheet
Executive Summary
Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Oversight and Investigations Subcommittee Chairman Bart Stupak ask infant formula makers Abbott, Mead Johnson, Nestle and PBM to voluntarily remove the chemical bisphenol A from their infant formula packaging. Dingell and Stupak in April asked FDA to reconsider BPA's safety in infant products (1"The Tan Sheet" April 12, 2008, In Brief). "We believe this measure will help protect developing infants and children from the neural, behavioral and developmental risks of BPA" and provide reassurance to concerned parents, the congressmen say in their May 6 letter to the firms. The lawmakers ask the companies to respond in writing to their letter and deliver a response to subcommittee no later than May 20...
You may also be interested in...
FDA Shift On BPA May Tighten Squeeze On Infant Formula Manufacturers
FDA's shift in position regarding the safety of bisphenol A likely will expedite the trend toward BPA-free packaging among infant formula marketers, even though existing science does not demonstrate a proven threat to babies and children
Bisphenol A safe?
Results of National Toxicology Program research prompt Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Bart Stupak, Oversight and Investigations Subcommittee, to ask FDA to reconsider the safety of the chemical bisphenol A in products intended for use by infants and children. In an April 14 draft brief, the NTP concludes there is "some concern for neural and behavioral effects in fetuses, infants, and children at current human exposures" and "the possibility that bisphenol A may alter human development cannot be dismissed." Stupak says FDA relied on two industry-funded studies to determine the chemical's safety while other authorities "used all available data to reach vastly different conclusions"...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”